Savara Inc Business Acquisition, Purchase Price Allocation, Assets Acquired (Liabilities Assumed), Net (Deprecated 2013-01-31)
Savara Inc (SVRA) had Business Acquisition, Purchase Price Allocation, Assets Acquired (Liabilities Assumed), Net (Deprecated 2013-01-31) of $6.70 million as of 2011-04-08, per its 10-Q filed 2013-05-15.
Discontinued › Notes › Business Combinations
us-gaap:BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNet · last filed 2013-05-15
- 2011-04-08: Business Acquisition, Purchase Price Allocation, Assets Acquired (Liabilities Assumed), Net (Deprecated 2013-01-31) $6.70M.
| Period end | Business Acquisition, Purchase Price Allocation, Assets Acquired (Liabilities Assumed), Net (Deprecated 2013-01-31) |
|---|---|
| 2011-04-08 | $6.70M 10-Q · filed 2013-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |